TrialCancer science2018

Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.

Seiichiro Ozono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.